125 related articles for article (PubMed ID: 12732845)
1. Coordinated intrahepatic and extrahepatic regulation of cytochrome p4502D6 in healthy subjects and in patients after liver transplantation.
Carcillo JA; Adedoyin A; Burckart GJ; Frye RF; Venkataramanan R; Knoll C; Thummel K; Roskos L; Wilson JW; Sereika S; Romkes M; Bebia Z; Branch RA
Clin Pharmacol Ther; 2003 May; 73(5):456-67. PubMed ID: 12732845
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers.
Carcillo JA; Parise RA; Adedoyin A; Frye R; Branch RA; Romkes M
Res Commun Mol Pathol Pharmacol; 1996 Feb; 91(2):149-159. PubMed ID: 8832907
[TBL] [Abstract][Full Text] [Related]
3. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR
Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337
[TBL] [Abstract][Full Text] [Related]
5. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
[TBL] [Abstract][Full Text] [Related]
6. Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate.
McConnachie L; Bodor M; Kowdley K; Levy A; Tung B; Thummel K; Phillips B; Bajpai M; Chi V; Esmay JD; Shen DD; Ho RJ
Clin Pharmacol Ther; 2004 Apr; 75(4):282-97. PubMed ID: 15060507
[TBL] [Abstract][Full Text] [Related]
7. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
9. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
[TBL] [Abstract][Full Text] [Related]
10. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
12. Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6.
Shimada T; Tsumura F; Yamazaki H; Guengerich FP; Inoue K
Pharmacogenetics; 2001 Mar; 11(2):143-56. PubMed ID: 11266079
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.
Haas CE; Brazeau D; Cloen D; Booker BM; Frerichs V; Zaranek C; Frye RF; Kufel T
Eur J Clin Pharmacol; 2005 Sep; 61(8):583-93. PubMed ID: 16041547
[TBL] [Abstract][Full Text] [Related]
14. Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling.
Lightfoot T; Ellis SW; Mahling J; Ackland MJ; Blaney FE; Bijloo GJ; De Groot MJ; Vermeulen NP; Blackburn GM; Lennard MS; Tucker GT
Xenobiotica; 2000 Mar; 30(3):219-33. PubMed ID: 10752638
[TBL] [Abstract][Full Text] [Related]
15. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
[TBL] [Abstract][Full Text] [Related]
17. Stability of debrisoquine (CYP2D6) phenotype in liver transplant patients.
Bendriss A; Bechtel Y; Paintaud G; Bendriss EK; Joanne C; Bresson-Hadni S; Magnette J; Becker MC; Gillet M; Mantion G
Ther Drug Monit; 1995 Apr; 17(2):113-9. PubMed ID: 7624897
[TBL] [Abstract][Full Text] [Related]
18. Only truncated, not complete cytochrome p450 2D6 RNA transcript and no detectable enzyme activity are expressed in human lymphocytes.
McConnachie LA; Phillips B; Bajpai M; Shen DD; Ho RJ
Drug Metab Dispos; 2003 Sep; 31(9):1103-7. PubMed ID: 12920165
[TBL] [Abstract][Full Text] [Related]
19. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
20. Debrisoquine metabolism and CYP2D expression in marmoset liver microsomes.
Cooke BR; Bligh SW; Cybulski ZR; Ioannides C; Hall M
Drug Metab Dispos; 2012 Jan; 40(1):70-5. PubMed ID: 21976620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
